Skip to main content
Top
Published in: BMC Clinical Pharmacology 1/2006

Open Access 01-12-2006 | Case report

Serum sickness-like reaction associated with cefazolin

Authors: Michael Brucculeri, Marian Charlton, David Serur

Published in: BMC Clinical Pharmacology | Issue 1/2006

Login to get access

Abstract

Background

Although rare, serum sickness-like reactions have been documented to occur following the administration of many antibiotics. Cefazolin, a first generation cephalosporin, is a commonly prescribed antibiotic which is considered to be generally safe and well tolerated. There have been no prior reports linking this drug with sickness-like reactions. We report a probable case of serum sickness-like reaction following a single dose of cefazolin.

Case Presentation

A 23 year old man with no significant past medical history was admitted to undergo a laparoscopic donor nephrectomy as part of a living-related renal transplant. One gram of intravenous cefazolin was administered perioperatively. The surgery was completed without complication and the remainder of his hospital course was uneventful. Ten days following discharge the patient developed fevers, painful and swollen joints, and a cutaneous eruption overlying his trunk and extremities. There was no evidence of systemic vasculitis. These clinical findings were most consistent with a serum sickness-like reaction. A brief course of corticosteroids and antihistaminergic therapy was initiated, and complete resolution of the patient's symptoms followed. The Naranjo probability scale indicated that this adverse drug event was probable.

Conclusion

Serum sickness-like reaction may be associated with cefazolin therapy.
Appendix
Available only for authorised users
Literature
2.
go back to reference Guharoy SR: Serum sickness secondary to ciprofloxacin use. Vet Hum Toxicol. 1994, 36: 540-1.PubMed Guharoy SR: Serum sickness secondary to ciprofloxacin use. Vet Hum Toxicol. 1994, 36: 540-1.PubMed
3.
go back to reference Elkayam O, Yaron M, Caspi D: Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum. 1999, 28: 392-7. 10.1016/S0049-0172(99)80004-3.CrossRefPubMed Elkayam O, Yaron M, Caspi D: Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum. 1999, 28: 392-7. 10.1016/S0049-0172(99)80004-3.CrossRefPubMed
4.
go back to reference Lowery N, Kearns GL, Young RA, Wheeler JG: Serum sickness-like reactions associated with cefprozil therapy. J Pediatr. 1994, 125: 325-8. 10.1016/S0022-3476(94)70220-9.CrossRefPubMed Lowery N, Kearns GL, Young RA, Wheeler JG: Serum sickness-like reactions associated with cefprozil therapy. J Pediatr. 1994, 125: 325-8. 10.1016/S0022-3476(94)70220-9.CrossRefPubMed
5.
go back to reference Vial T, Pont J, Pham E, Rabilloud M, Descotes J: Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992, 26: 910-4.PubMed Vial T, Pont J, Pham E, Rabilloud M, Descotes J: Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992, 26: 910-4.PubMed
7.
8.
go back to reference Yerushalmi J, Zvulunov A, Halevy S: Serum sickness-like reactions. Cutis. 2002, 69: 395-7.PubMed Yerushalmi J, Zvulunov A, Halevy S: Serum sickness-like reactions. Cutis. 2002, 69: 395-7.PubMed
9.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-45.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-45.CrossRefPubMed
Metadata
Title
Serum sickness-like reaction associated with cefazolin
Authors
Michael Brucculeri
Marian Charlton
David Serur
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Clinical Pharmacology / Issue 1/2006
Electronic ISSN: 1472-6904
DOI
https://doi.org/10.1186/1472-6904-6-3

Other articles of this Issue 1/2006

BMC Clinical Pharmacology 1/2006 Go to the issue